StreetInsider.com News Articles

H.C. Wainwright Reiterates Buy Rating on Biodesix (BDSX)

Thu, 22 Oct 2026 08:10:28 -0400

H.C. Wainwright analyst Yi Chen reiterated a Buy rating and $38.00 price target on Biodesix (NASDAQ: BDSX).

The analyst commented: "Earlier this week, Biodesix announced that the American College of Chest Physicians (CHEST) had published a new framework for clinical practice, which describes six steps to building a comprehensive lung nodule program, with validated biomarker testing such as the Biodesix Nodify Lung tests, as a core component of standardizing risk stratification to guide clinical decisions. This new framework was developed by a multidisciplinary panel of nationally recognized interventional pulmonologists, thoracic surgeons, and diagnostic radiologists, representing leading hospitals and health systems throughout

Biodesix to Report Third Quarter 2026 Financial Results on November 5, 2026

Thu, 22 Oct 2026 06:00:00 -0400

LOUISVILLE, Colo., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that it will release financial results for the third quarter ended September 30, 2026 after the close of trading on Thursday, November 5. Biodesix management will host a conference call and webcast to discuss its financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day.

Listeners can register for the webcast via this link. Analysts who wish to participate in the question and answer session

Biodesix to Report Third Quarter 2026 Financial Results on November 5, 2026

Thu, 22 Oct 2026 06:00:00 -0400

Listeners can register for the webcast via this link. Analysts who wish to participate in the question and answer session

American College of Chest Physicians Publishes New Framework for Lung Nodule Programs Recommending Biomarkers for Risk Stratification

Mon, 19 Oct 2026 16:01:00 -0400

New CHEST framework developed by a renowned multidisciplinary panel with expertise in building and managing lung nodule programs across diverse clinical practices

LOUISVILLE, Colo., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc (NASDAQ: BDSX), a leader in diagnostic solutions, today announced that the American College of Chest Physicians (CHEST) has published a new framework for clinical practice, “Building a Lung Nodule Program: From Detection to Diagnosis.” This groundbreaking framework describes six steps to building a comprehensive lung nodule program, with validated biomarker testing, such as the Biodesix Nodify Lung® tests, as a core component of standardizing risk stratification to

American College of Chest Physicians Publishes New Framework for Lung Nodule Programs Recommending Biomarkers for Risk Stratification

Mon, 19 Oct 2026 16:01:00 -0400

New CHEST framework developed by a renowned multidisciplinary panel with expertise in building and managing lung nodule programs across diverse clinical practices

Biodesix launches digital diagnostics unit with Vanderbilt partnership

Mon, 19 Oct 2026 06:02:00 -0400

Biodesix, Inc. (Nasdaq: BDSX) announced the addition of a Digital Diagnostics initiative to its lung diagnostics strategy, establishing what the company describes as a multimodal diagnostic platform combining blood-based biomarkers, imaging biomarkers, and artificial intelligence.

The first product under the initiative is a radiomics-based test for lung nodule risk assessment, developed in partnership with Vanderbilt University and Vanderbilt Health. The test applies AI to extract quantitative features from CT scans and is designed to complement Biodesix's existing Nodify Lung blood-based test portfolio. Commercial availability is anticipated in 2028.

Initial performance data for the test is scheduled to be presented at the RSNA

Biodesix launches digital diagnostics unit with Vanderbilt partnership

Mon, 19 Oct 2026 06:02:00 -0400

Initial performance data for the test is scheduled to be presented at the RSNA

Biodesix Adds Digital Diagnostics to Lung Pipeline, Creating New Growth Platform Combining Blood and Imaging Biomarkers

Mon, 19 Oct 2026 06:00:00 -0400

Partnership with Vanderbilt University and Vanderbilt Health accelerates development of the first radiomics-based test for lung nodule risk assessment

LOUISVILLE, Colo., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, today announced the addition of Digital Diagnostics to its Lung Diagnostics strategy, establishing the foundation for a multimodal diagnostic platform that combines blood-based biomarkers, imaging biomarkers, and artificial intelligence. The first product, a radiomics-based test for lung nodule risk assessment developed with Vanderbilt University and Vanderbilt Health, is designed to complement the Nodify Lung® portfolio and represents the next phase of innovation in

Biodesix Adds Digital Diagnostics to Lung Pipeline, Creating New Growth Platform Combining Blood and Imaging Biomarkers

Mon, 19 Oct 2026 06:00:00 -0400

Partnership with Vanderbilt University and Vanderbilt Health accelerates development of the first radiomics-based test for lung nodule risk assessment

Biodesix (BDSX) PT Raised to $40 at TD Cowen

Tue, 13 Oct 2026 09:32:02 -0400

TD Cowen analyst Dan Brennan raised the price target on Biodesix (NASDAQ: BDSX) to $40.00 (from $30.00) while maintaining a rating.

Biodesix to Present New Real-World Evidence Supporting Integration of Nodify Lung® Testing into Routine Lung Nodule Care at CHEST 2026

Tue, 13 Oct 2026 06:00:00 -0400

New sponsored and independent research evaluates clinical utility, patient follow-up, and diagnostic test sequencing

LOUISVILLE, Colo., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, today announced multiple presentations at CHEST 2026 highlighting how Nodify Lung testing is being incorporated into real-world lung nodule management. The presentations build upon the strong evidence base with new use cases and clinical comparisons, illustrating how blood-based lung nodule risk assessment guides clinical decision-making, affects patient adherence to follow-up, and optimizes the use of imaging and other diagnostic procedures.

New analyses from the CLARIFY study,

Biodesix to Present New Real-World Evidence Supporting Integration of Nodify Lung® Testing into Routine Lung Nodule Care at CHEST 2026

Tue, 13 Oct 2026 06:00:00 -0400

New sponsored and independent research evaluates clinical utility, patient follow-up, and diagnostic test sequencing

New analyses from the CLARIFY study,

Form 4 BIODESIX INC For: Sep 30 Filed by: PATIENCE JOHN

Fri, 02 Oct 2026 16:13:00 -0400

si-local-file:///var/storage/secattach/20261002/27142367.html

Biodesix (BDSX) PT Raised to $38 at H.C. Wainwright

Mon, 28 Sep 2026 06:55:56 -0400

H.C. Wainwright analyst Yi Chen raised the price target on Biodesix (NASDAQ: BDSX) to $38.00 (from $27.00) while maintaining a Buy rating.

Biodesix (BDSX) PT Raised to $38 at H.C. Wainwright

Fri, 25 Sep 2026 12:53:45 -0400

H.C. Wainwright analyst Yi Chen raised the price target on Biodesix (NASDAQ: BDSX) to $38.00 while maintaining a Buy rating.

Biodesix advances two MRD monitoring programs with Bio-Rad and Thermo Fisher

Thu, 24 Sep 2026 06:00:48 -0400

Biodesix, Inc. (Nasdaq: BDSX) announced progress in two collaborative programs for Molecular Residual Disease (MRD) monitoring, one tumor-informed and one tumor-naïve, both designed to detect circulating tumor DNA (ctDNA) in blood to assess whether cancer remains or is returning after treatment.

The tumor-informed solution, developed through a multi-year collaboration with Bio-Rad Laboratories, uses Biodesix's Diagnostic Cortex bioinformatics platform to identify genomic changes unique to a patient's tumor. Bio-Rad's Droplet Digital PCR technology then tracks those changes in blood, detecting ctDNA below 1 part per million of total DNA in a blood sample.

The tumor-naïve solution is part of a newly launched program

Biodesix advances two MRD monitoring programs with Bio-Rad and Thermo Fisher

Thu, 24 Sep 2026 06:00:48 -0400

The tumor-naïve solution is part of a newly launched program

Biodesix advances two MRD monitoring programs with Bio-Rad and Thermo Fisher

Thu, 24 Sep 2026 06:00:48 -0400

The tumor-naïve solution is part of a newly launched program

Biodesix Advances Two Complementary Approaches to Molecular Residual Disease (MRD) Monitoring

Thu, 24 Sep 2026 06:00:00 -0400

Biodesix-led tumor-informed and tumor-naïve programs draw on the company’s bioinformatics and diagnostics test development expertise

LOUISVILLE, Colo., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, today announced strategic progress in two collaborative programs for tumor-informed and tumor-naïve Molecular Residual Disease (MRD) solutions intended to support cancer centers and clinical laboratories. Both solutions detect circulating tumor DNA (ctDNA), the tumor DNA that a cancer sheds into the blood, to assess whether disease remains or is returning after treatment. The tumor-informed solution is the result of a multi-year collaboration with Bio-Rad Laboratories. The tumor-naïve

Biodesix Advances Two Complementary Approaches to Molecular Residual Disease (MRD) Monitoring

Thu, 24 Sep 2026 06:00:00 -0400

Biodesix-led tumor-informed and tumor-naïve programs draw on the company’s bioinformatics and diagnostics test development expertise

Biodesix Quality and Regulatory Executive, Brianna Phillips, to speak at upcoming RAPS and SOCRA Annual Meetings

Mon, 14 Sep 2026 16:01:00 -0400

Industry-leading QA/RA excellence accelerates patient access to Biodesix Lab testing, which helps improve overall outcomes for patients with lung nodules

LOUISVILLE, Colo., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, today announced that Brianna Phillips, Vice President of Quality and Regulatory Affairs at Biodesix, will be presenting at the upcoming Regulatory Affairs Professionals Society (RAPS) and Society of Clinical Research Associates (SOCRA) Annual Meetings.

These important professional society meetings put a spotlight on the material influence and need for Quality Affairs and Regulatory Affairs (QA/RA) expertise in the medical diagnostics

Biodesix Quality and Regulatory Executive, Brianna Phillips, to speak at upcoming RAPS and SOCRA Annual Meetings

Mon, 14 Sep 2026 16:01:00 -0400

Industry-leading QA/RA excellence accelerates patient access to Biodesix Lab testing, which helps improve overall outcomes for patients with lung nodules

These important professional society meetings put a spotlight on the material influence and need for Quality Affairs and Regulatory Affairs (QA/RA) expertise in the medical diagnostics

Biodesix to Participate in Upcoming Investor Conferences

Thu, 03 Sep 2026 06:00:00 -0400

LOUISVILLE, Colo., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, today announced that members of the Biodesix leadership team will present in three upcoming investor conferences:

Lake Street Capital Markets’ 10^th Annual Best Ideas Growth (BIG10) Conference
1x1 meetings only
Date: Thursday, September 10
Location: New York, NY

H.C. Wainwright 28^th Annual Global Investment Conference
1x1 meetings only
Date: Tuesday, September 15
Location: New York

5^th Annual Roth Healthcare Opportunities Conference
Panel and 1x1 meetings
Panel Title: The Rise of MRD Monitoring in Solid Tumors, and

Biodesix to Participate in Upcoming Investor Conferences

Thu, 03 Sep 2026 06:00:00 -0400

Lake Street Capital Markets’ 10^th Annual Best Ideas Growth (BIG10) Conference
1x1 meetings only
Date: Thursday, September 10
Location: New York, NY

H.C. Wainwright 28^th Annual Global Investment Conference
1x1 meetings only
Date: Tuesday, September 15
Location: New York

5^th Annual Roth Healthcare Opportunities Conference
Panel and 1x1 meetings
Panel Title: The Rise of MRD Monitoring in Solid Tumors, and

Form 4 BIODESIX INC For: Aug 12 Filed by: SCHULER JACK W

Thu, 13 Aug 2026 17:23:00 -0400

si-local-file:///var/storage/secattach/20260813/26922818.html